Novartis Says Kisqali Significantly Lowered the Risk of Cancer Recurrence

   By Giulia Petroni 
 

Novartis said that primary endpoint data from a Phase 3 trial showed that ribociclib drug treatment Kisqali significantly reduced the risk of cancer recurrence across a broad population of patients with early breast cancer.

The Swiss pharma giant on Friday said that ribociclib combined with endocrine therapy lowered the risk of cancer recurrence by 25.2% in patients compared to endocrine therapy alone, according to data from the Natalee trial.

The patients suffer from stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, according to the company.

"Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with early breast cancer, regardless of disease stage, menopausal or nodal status," Novartis said.

Novartis plans to submit Phase 3 data to regulatory authorities in the U.S. and Europe before end of year.

Write to Giulia Petroni at [e-mail]

(END) Dow Jones Newswires

June 02, 2023 08:33 ET (12:33 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.